SCHEMBL6565552

SCHEMBL6565552

COc1cccc(P(c2ccccc2)c2ccccc2)c1-c1c(OC)cccc1P(c1ccccc1)c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 4/20 0.44
CA2 P00918 4/20 0.44
CA7 P43166 3/20 0.44
CA9 Q16790 3/20 0.44
CA12 O43570 2/20 0.44
CA14 Q9ULX7 2/20 0.44
CA4 P22748 1/20 0.44
DRD1 P21728 2/20 0.41
TDP1 Q9NUW8 4/20 0.41
CYP3A4 P08684 2/20 0.41
TOP1 P11387 1/20 0.38
ALDH1A1 P00352 5/20 0.38
TP53 P04637 2/20 0.38
TSHR P16473 1/20 0.38
ADRA2B P18089 1/20 0.38
PTGS1 P23219 1/20 0.38
MAPT P10636 3/20 0.37
KDM4E B2RXH2 2/20 0.37
MEN1 O00255 1/20 0.37
USP2 O75604 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29430119 1.00 CA1 (0.44) CA1CA2CA7CA9CA12
SCHEMBL301296 1.00 CA1 (0.44) CA1CA2CA7CA9CA12
SCHEMBL29407955 1.00 CA1 (0.44) CA1CA2CA7CA9CA12
SCHEMBL1768301 0.98 CA1 (0.43) CA1CA2CA7CA9CA12
SCHEMBL13593792 0.92 CA1 (0.38) CA1CA2CA7CA9CA12
SCHEMBL12083834 0.92 CA12 (0.38) CA1CA2CA7CA9CA12
SCHEMBL7289398 0.90 CA1 (0.36) CA1CA2CA7CA9CA12
SCHEMBL5573142 0.90 CA1 (0.36) CA1CA2CA7CA9CA12
SCHEMBL5195630 0.90 APP (0.44) CA1CA2CA7CA9CA12
SCHEMBL1768406 0.90 TOP1 (0.41) CA1CA2CA7CA9CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1373192-A1 N-PHENPROPYLCYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS NEP INHIBITORS FOR FSAD Pfizer Limited (GB) 2004-01-02 EP disclosed
US-6660756-B2 N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase PFIZER INC. 2003-12-09 US disclosed
US-20030105132-A1 N-phenpropylcuclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase PFIZER INC. 2003-06-05 US disclosed
WO-2002079143-A1 N-PHENPROPYLCYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS NEP INHIBITORS FOR FSAD PFIZER LIMITED (GB) 2002-10-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105132-A1 N-phenpropylcuclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase PREP, ENGASE, ENPEP CA1 380/4885CA2 279/4885CA7 461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.